BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Sarcomas AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Treatment
62 results:

  • 1. treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go.
    Longo V; Catino A; Montrone M; Montagna ES; Pesola F; Marech I; Pizzutilo P; Nardone A; Perrone A; Gesualdo M; Galetta D
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542211
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Pharmacology and pharmacokinetics of tazemetostat.
    Orleni M; Beumer JH
    Cancer Chemother Pharmacol; 2024 May; 93(5):509-517. PubMed ID: 38520556
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma.
    Xie L; Sun X; Xu J; Liang X; Liu K; Sun K; Yang R; Tang X; Guo W
    BMC Cancer; 2024 Feb; 24(1):172. PubMed ID: 38310286
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. A miniaturized mode-of-action profiling platform enables high throughput characterization of the molecular and cellular dynamics of ezh2 inhibition.
    Falkenstern L; Georgi V; Bunse S; Badock V; Husemann M; Roehn U; Stellfeld T; Fitzgerald M; Ferrara S; Stöckigt D; Stresemann C; Hartung IV; Fernández-Montalván A
    Sci Rep; 2024 Jan; 14(1):1739. PubMed ID: 38242973
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Pharmacological ezh2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells.
    O'Brien E; Tse C; Tracy I; Reddin I; Selfe J; Gibson J; Tapper W; Pengelly RJ; Gao J; Aladowicz E; Petts G; Thway K; Popov S; Kelsey A; Underwood TJ; Shipley J; Walters ZS
    Clin Epigenetics; 2023 Oct; 15(1):167. PubMed ID: 37858275
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets.
    Høland M; Berg KCG; Eilertsen IA; Bjerkehagen B; Kolberg M; Boye K; Lingjærde OC; Guren TK; Mandahl N; van den Berg E; Palmerini E; Smeland S; Picci P; Mertens F; Sveen A; Lothe RA
    EBioMedicine; 2023 Nov; 97():104829. PubMed ID: 37837931
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Delayed diagnosis of pediatric intra-articular epithelioid sarcoma: a case report and literature review.
    Zhang R; Liu J; Liu L; Lin Y; Zhang Q
    BMC Pediatr; 2023 Sep; 23(1):488. PubMed ID: 37752442
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Pharmacotherapeutic strategies for epithelioid sarcoma: are we any closer to a non-surgical cure?
    Meissner M; Napolitano A; Thway K; Huang P; Jones RL
    Expert Opin Pharmacother; 2023; 24(12):1395-1401. PubMed ID: 37326105
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Tazemetostat for tumors harboring SMARCB1/SMARCA4 or ezh2 alterations: results from NCI-COG pediatric MATCH APEC1621C.
    Chi SN; Yi JS; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey BD; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Jaju A; Mhlanga JC; Fox E; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW
    J Natl Cancer Inst; 2023 Nov; 115(11):1355-1363. PubMed ID: 37228094
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Dysregulation of iron homeostasis by TfR-1 renders ezh2 wild type diffuse large B-cell lymphoma resistance to ezh2 inhibition.
    Yu L; Wang YF; Xiao J; Shen QQ; Chi SS; Gao YL; Lin DZ; Ding J; Fang YF; Chen Y
    Acta Pharmacol Sin; 2023 Oct; 44(10):2113-2124. PubMed ID: 37225847
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. New targeted treatments for advanced sarcomas.
    Li CC; Chen TW
    Curr Opin Oncol; 2023 Jul; 35(4):309-314. PubMed ID: 37222206
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Capsaicin Reduces Cancer Stemness and Inhibits Metastasis by Downregulating
    Chen ZY; Huang HH; Li QC; Zhan FB; Wang LB; He T; Yang CH; Wang Y; Zhang Y; Quan ZX
    Am J Chin Med; 2023; 51(4):1041-1066. PubMed ID: 37120706
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. ezh2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression.
    Lin ZS; Chung CC; Liu YC; Chang CH; Liu HC; Liang YY; Huang TL; Chen TM; Lee CH; Tang CH; Hung MC; Chen YH
    Elife; 2023 Jan; 12():. PubMed ID: 36622753
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Alpha Ketoglutarate Downregulates the Neutral Endopeptidase and Enhances the Growth Inhibitory Activity of Thiorphan in Highly Aggressive Osteosarcoma Cells.
    Mizerska-Kowalska M; Sławińska-Brych A; Niedziela E; Brodovskiy V; Zdzisińska B
    Molecules; 2022 Dec; 28(1):. PubMed ID: 36615293
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Identification and treatment of SMARCA4 Deficient Poorly Differentiated Gastric Carcinoma.
    Bhat V; Koneru M; Knapp K; Joneja U; Morrison J; Hong YK
    Am Surg; 2023 Nov; 89(11):4987-4989. PubMed ID: 36533880
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. ezh2 promotes the progression of osteosarcoma through the activation of the AKT/GSK3β pathway.
    Wan D; Han X; Zhang C; Zhang Y; Ma Y; Wang G
    Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1179-1186. PubMed ID: 35818168
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Chemical biology and pharmacology of histone lysine methylation inhibitors.
    Barghout SH; Machado RAC; Barsyte-Lovejoy D
    Biochim Biophys Acta Gene Regul Mech; 2022 Aug; 1865(6):194840. PubMed ID: 35753676
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon ezh2 inhibition.
    Drosos Y; Myers JA; Xu B; Mathias KM; Beane EC; Radko-Juettner S; Mobley RJ; Larsen ME; Piccioni F; Ma X; Low J; Hansen BS; Peters ST; Bhanu NV; Dhanda SK; Chen T; Upadhyaya SA; Pruett-Miller SM; Root DE; Garcia BA; Partridge JF; Roberts CWM
    Mol Cell; 2022 Jul; 82(13):2472-2489.e8. PubMed ID: 35537449
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Targeting Enhancer of Zeste Homolog 2 for the treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects.
    Xia J; Li J; Tian L; Ren X; Liu C; Liang C
    J Med Chem; 2022 May; 65(10):7016-7043. PubMed ID: 35531606
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. ezh2 Inhibitors Suppress Colorectal Cancer by Regulating Macrophage Polarization in the Tumor Microenvironment.
    Li C; Song J; Guo Z; Gong Y; Zhang T; Huang J; Cheng R; Yu X; Li Y; Chen L; Ma X; Sun Y; Wang Y; Xue L
    Front Immunol; 2022; 13():857808. PubMed ID: 35432300
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.